SLC5A2 and type 2 diabetes mellitus: The pharmacological armamentarium against T2DM, including mainstays like metformin and SGLT2 inhibitors, has largely been developed around a “single-target, high-potency” paradigm, effectively addressing specific physiological pathways such as hepatic gluconeogenesis or renal glucose reabsorption (44).